Document:

Services Agreement

 Exhibit 10.21 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

SERVICES AGREEMENT (DP) 
 This Services Agreement (DP) (this “Agreement”), is dated as of this 15th day of March, 2011 (the “Signature Date”), by and between Genomatica, Inc., a Delaware
corporation with principal offices located at 10520 Wateridge Circle, San Diego, California 92121 (hereinafter referred to as “Genomatica”), and Tate & Lyle Ingredients Americas, Inc., a Delaware corporation with principal
offices located at 2200 East Eldorado Street, Decatur, Illinois 62521 (hereinafter referred to as “T&L”). 

RECITALS: 

WHEREAS, Genomatica and T&L are concurrently with the execution of this Agreement entering into a Joint Development Agreement (the
“JDA”; capitalized terms used but not defined in this Agreement shall have the meanings assigned to them in the JDA); and 
 WHEREAS, Section 3.1(b) of the JDA contemplates that T&L shall provide the services set forth herein during the Demonstration Phase in consideration of certain fees to be paid to T&L in the
event that Genomatica enters into the Demonstration Phase. 
 NOW THEREFORE, Genomatica and T&L agree to the following terms
and conditions: 
  

	1	SERVICES 

 1.1 From and
after the date on which Genomatica provides T&L with written notice pursuant to Section 3.2(a) of the JDA that Genomatica is electing to enter into the Demonstration Phase (the “Services Effective Date”) until the
expiration or earlier termination of this Agreement pursuant to Section 8 (the “Term”), T&L shall provide (a) the services reasonably necessary to perform [...***...] (the “Lab Scale Services”)
in the fermentation lab facilities located at Building 59 (the “Lab Facility”) and (b) the services reasonably necessary to [...***...] (the “Demonstration Services” and, together with the Lab Scale
Services, the “Services”) at the T&L Decatur, Illinois demonstration plant, Building 119 (the “Pilot Plant”). For clarification, the Services shall include any services to be performed by T&L during the
Demonstration Phase as described in the Development Plan and the JDA except as otherwise agreed to by the JDC in accordance with the JDA. 
 1.2 The Parties agree that the scope of this Agreement comprises all activities necessary for performance of the Services, including without limitation, the sourcing and storage of the Raw Materials (as
defined in Section 5.1), the conduct of the experiments at the Lab Facility and the Pilot Plant, the development of the products set forth on 

  

					
		  	1	  	***Confidential Treatment Requested

 
Annex A (the “Products”), Product testing, Product storage and by-product handling, all in accordance with standard operating procedures (“SOPs”). The
Parties agree that the SOPs shall be developed by [...***...]. The SOPs may be revised, including but not limited to revisions to incorporate written instructions or policies provided by Genomatica, upon approval by the JDC, which approval
shall not be unreasonably withheld. 
 1.3 T&L shall provide staffing at the Lab Facility and the Pilot Plant as set forth
in the Development Plan; provided, that the [...***...] process engineering roles at the Pilot Plant may be filled by employees of either Party upon mutual agreement. If any of such process engineering roles are filled by Genomatica employees,
there will be a reduction in the Demonstration Fee (as defined in Section 6.1) by the amount allocated for such process engineering roles in the Development Plan to reflect that T&L will not be providing such staffing. The JDC will
determine the timing for phasing in such staffing and related costs. 
 1.4 T&L may, directly or through one or more
Affiliates, hire or engage one or more Third Parties (each, a “Subcontractor”) to perform any or all of the Services; provided, that T&L shall remain responsible for ensuring that the obligations with respect to the performance
of the Services are satisfied with respect to any Service provided by any Subcontractor, and any such Subcontractor shall be subject to a binding written obligation consistent with the provisions regarding ownership of Intellectual Property set
forth in Article VIII of the JDA and the provisions regarding confidentiality set forth in Article X of the JDA. 

1.5 Genomatica shall furnish T&L with all Genomatica Intellectual Property directly relevant to the Joint Development Program within
the Territory which Genomatica or T&L deems reasonably necessary for delivery to T&L in order for T&L to perform the Services pursuant to the limited license granted under Section 9.1 of the JDA. In addition, Genomatica shall
provide T&L with such assistance as may be reasonably requested by T&L in order to assist T&L in the performance of the Services. Without limiting the foregoing, Genomatica shall provide T&L with (a) analytical procedures
consistent with the Genomatica technology package and (b) a technical design team knowledgeable of Genomatica’s basic data package and material and energy balance and consisting of people with the following areas of expertise:
[...***...]. Such Genomatica personnel shall be available onsite at the Pilot Plant as determined by the JDC. 
  

	2	JOINT DEVELOPMENT COMMITTEE 

 In order to support the performance of the Services, the JDC, operating in accordance with the procedures set forth in Article V of the JDA, shall perform the activities described below, in addition to
such other activities as the Parties agree in writing that the JDC may undertake: 

  

					
		  	2	  	***Confidential Treatment Requested

 2.1 The JDC shall be responsible for the development of [...***...] (the
“Project Plan”). In all cases, the foregoing shall be consistent with the Development Plan. 
 2.2 The JDC
shall be responsible for monitoring the operation of the Pilot Plant, without limiting T&L’s responsibility for providing the Services in accordance with the SOPs, and for approving the Project Plan and approving and managing the budget for
the Designs, the EPC Activities, the Equipment and related costs, which shall be consistent with the Development Plan, including the budget for the Demonstration Phase included therein. 

2.3 The JDC shall be responsible for setting the best practices to be observed at the Pilot Plant and in providing the Services. The JDC
shall also be required to analyze and approve the Designs and the SOPs. 
  

	3	LICENSES AND APPROVALS 

3.1 Subject to Section 6.1 of the JDA, T&L shall use commercially reasonable efforts to timely obtain and maintain, at its sole
cost and expense and for the duration of this Agreement, all approvals, permits and licenses necessary for the performance of its obligations under this Agreement. 
 3.2 Genomatica shall use commercially reasonable efforts to obtain and maintain, [...***...], for the duration of this Agreement, all approvals and licenses necessary for the Products. T&L,
[...***...], shall support Genomatica in the process of obtaining such Products’ approvals and licenses, by means of providing to Genomatica all documents and information in T&L’s possession that are reasonably requested by
Genomatica. 
  

	4	PURCHASING OF EQUIPMENT; EXPANSION AND INSURANCE  

 4.1 The Parties are aware that the provision of the Services requires the acquisition of certain custom equipment specifically designed for and to be used exclusively for the development of the Products
(the “Specialized Equipment”) and certain non-custom equipment that is not specific to the development of the Products (the “General Equipment,” and together with the Specialized Equipment, the
“Equipment”), in each case as provided in the Development Plan. The Parties agree that T&L, under the direction of the JDC, shall procure and contract the engineering services and the necessary Equipment for the expansion of the
Pilot Plant, including the installation of the Equipment, to facilitate the development of the Products (the “Expansion”) and shall oversee all work performed and services provided with respect to the installation of the Equipment
and the Expansion; provided, that Genomatica shall make payments for the Equipment and services for the Expansion directly to the vendors thereof or, promptly upon request, shall reimburse T&L for the costs of such Equipment

  

					
		  	3	  	***Confidential Treatment Requested

 
and services, subject to reimbursement under the Commercialization Agreement (if applicable); provided, that Genomatica shall make payments to T&L in advance for any capital expenditures.
T&L shall, to the extent commercially feasible, assist Genomatica in obtaining the best available prices for the Equipment. T&L shall keep the JDC apprised of any projected cost overruns for the Expansion, and any such overruns must be
approved by the JDC. Section 7.2 of the JDA shall apply with respect to all such Equipment. For clarification, the Services shall include maintenance of such Equipment (costs of which are included in the Fee) and coordination of repair of such
Equipment, costs of which repairs are not included in the Fee and would be at Genomatica’s expense. 
 4.2
[...***...] for modifications to the Pilot Plant that may be needed to support the installation and operation of the Equipment in accordance with the Development Plan, subject to reimbursement under the Commercialization Agreement (if
applicable)]. In the event additional modifications not specified in the Development Plan become necessary, [...***...] shall submit a description of the reason for and nature and projected cost of the modifications to the JDC. 

4.3 During the Term, [...***...], shall obtain and maintain insurance for the Lab Facility, the Pilot Plant and the Equipment in
accordance with Annex B; [...***...]. 
  

	5	SUPPLY OF RAW MATERIALS; PRODUCT STORAGE AND SHIPMENT 

 5.1 T&L shall be solely responsible for procurement and receipt of raw materials described on Annex C (“Raw Materials”) and for providing all utilities and ancillary
infrastructure necessary to perform the Services in the Lab Facility and the Pilot Plant, including, without limitation, water and waste facilities, electricity, steam, and phone and internet services. 

5.2 T&L shall use commercially reasonable efforts to procure Raw Materials conforming to the specifications contained in the SOPs in
such quantities and at such times as required to enable development of the Products required under the Development Plan. 
 5.3
During the Term, Genomatica [...***...] shall obtain and maintain product liability insurance in commercially reasonable amounts for the Products. 
 5.4 T&L shall be solely responsible for the handling and storage of Raw Materials at the Pilot Plant, which shall be done in accordance with the SOPs, including insuring against loss or damage to the
Raw Materials. 
 5.5 In addition to the Raw Materials, T&L shall be responsible for providing dextrose conforming to the
specifications set forth on Annex D in such quantities and at 

  

					
		  	4	  	***Confidential Treatment Requested

 
such times as required to enable development of the Products as required under the Development Plan. 
 5.6 T&L shall be responsible for storing the finished Products and for making the finished Products available for pickup by Genomatica or its designee at the Pilot Plant, in each case as specified in
the SOPs. Genomatica shall be responsible for arranging for the pickup of Products from the Pilot Plant at such times as T&L requests. It is anticipated that once per month during the Demonstration Phase, T&L would make a distillation run
and would make available Products produced during such run [...***...], Genomatica or its designee would pickup such totes within such time as Genomatica and T&L agree (but no more than thirty (30) days) after T&L notifies
Genomatica that such totes are available for pickup. The mode of final shipment shall be specified by Genomatica. [...***...]. 
 5.7 Subject to the terms of the JDA, all of the by-products (including spent biomass) from the manufacturing of Products shall be disposed of in a manner to be mutually agreed by the Parties. 

 

	6	PRICING; PAYMENT TERMS 

6.1 For each month during the Term, Genomatica shall pay T&L (i) for the Lab Scale Services a fixed fee of $[...***...] per
month (the “Lab Scale Fee”) and (ii) for the Demonstration Services a fixed fee of $[...***...] per month (the “Demonstration Fee” and, together with the Lab Scale Fee, the “Fee”). The
Demonstration Fee shall not commence until [...***...]. Commencing [...***...], the Fee shall increase (but not decrease) based [...***...]. 
 6.2 The Fee shall be due and payable by Genomatica to T&L on a monthly basis in advance. In addition, T&L shall issue to Genomatica by the [...***...] of each calendar month an invoice of
the Fee and all other amounts due and payable by Genomatica under this Agreement for the previous calendar month. Payment shall be due and payable by Genomatica to T&L within [...***...] days after receipt of an invoice. Genomatica shall
not be entitled to deduct or setoff the amount of any claim asserted against T&L against any monthly Fee or any other invoices. Restrictive endorsements or other statements on checks shall not apply to T&L. 

6.3 The currency for invoicing and payment shall be United States dollars. 

 

	7	LIMITATION OF LIABILITY; INDEMNIFICATION 

 7.1 Neither Party nor any of their respective Affiliates shall be liable to the other Party or its Affiliates for any losses or damages arising from any claim relating to

  

					
		  	5	  	***Confidential Treatment Requested

 
this Agreement or any of the Services to be provided hereunder or the performance of or failure to perform such Party’s obligations under this Agreement, except to the extent that such
losses or damages result or arise from (a) the negligence or willful misconduct of such Party or its respective Affiliates or (b) in the case of T&L, performance of the Services to the extent T&L or any of its Subcontractors does
not apply and follow the SOPs. Notwithstanding the foregoing, (i) T&L shall not be liable to Genomatica to the extent T&L and its Subcontractors, in performing the Services, apply and follow the SOPs, and Genomatica shall not be
entitled to indemnification for any losses or damages resulting or arising from performance of the Services to the extent T&L and its Subcontractors apply and follow the SOPs, and (ii) each Party’s cumulative aggregate liability to the
other Party and its Affiliates under this Agreement as described in the first sentence of this Section 7.1 with respect to any distillation run in any month during the term of this Agreement shall not exceed an amount equal to one
(1) month of Fees paid by Genomatica to T&L. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER, ITS AFFILIATES OR ANY THIRD PARTY FOR ANY SPECIAL OR CONSEQUENTIAL DAMAGES, REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT, IN TORT
INCLUDING NEGLIGENCE, BY STATUTE OR UNDER ANY QUASI-CONTRACTUAL THEORY OF LIABILITY, EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. The foregoing limitations of liability and damages will not apply and nothing in this Agreement
shall affect either Party’s liability for breach of any confidentiality obligation under this Agreement or the JDA or either Party’s indemnification obligations under Article XII of the JDA. 

7.2 Except for remedies that cannot be waived as a matter of law and injunctive and provisional relief (including specific performance)
and subject to the last sentence of Section 7.1, this Section 7 and Section 8 shall be the exclusive remedy in respect of the subject matter of this Agreement and the transactions contemplated hereby, including for breaches of this
Agreement (including any covenant, obligation, representation or warranty contained in this Agreement). 
 7.3 Except as
specifically provided in Article XI of the JDA, each Party disclaims all warranties of any kind, express or implied, to the fullest extent permitted by Law, including but not limited to the implied warranties of merchantability, fitness for
particular purpose and noninfringement. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY WITH REGARD TO THE SUCCESS OF THE SERVICES, THE JOINT DEVELOPMENT PROGRAM OR THE USEFULNESS OF ANY SERVICES, BACKGROUND INTELLECTUAL PROPERTY, PROCESS
INTELLECTUAL PROPERTY OR JDA INTELLECTUAL PROPERTY. 
  

	8	TERM; TERMINATION 

 8.1
This Agreement is entered into as of the Signature Date, but shall only become effective upon the Services Effective Date and shall continue (unless earlier terminated pursuant to Section 8.2) until September 15, 2013. 

8.2 This Agreement may be terminated: 

  
 6 

	 	(a)	by mutual written consent of T&L and Genomatica; 

  

	 	(b)	by either Party upon written notice to the other Party upon termination of the JDA; 

 

	 	(c)	by Genomatica at any time upon sixty (60) days’ prior written notice to T&L; 

 

	 	(d)	by Genomatica the event T&L has breached in any material respect any representation, warranty, covenant or agreement of T&L contained in this Agreement,
Genomatica has notified T&L of the breach, and the breach has continued without cure for a period of thirty (30) days after the notice of breach; or 

 

	 	(e)	by T&L in the event Genomatica has breached in any material respect any representation, warranty, covenant or agreement of Genomatica contained in this Agreement,
T&L has notified Genomatica of the breach, and the breach has continued without cure for a period of thirty (30) days after the notice of breach (other than for payment defaults for which the cure period shall be ten (10) days after
the receipt of notice). 

 8.3 Effect of Termination. Upon expiration or termination of this Agreement
pursuant to this Section 8, all rights and obligations of the Parties under this Agreement shall terminate, except as provided in this Section 8.3. Termination of this Agreement shall not relieve or release either Party of any right or
obligation which, at the time of such termination, has already accrued to such Party or which is attributable to a period prior to such termination (including, without limitation, the payment of all Fees due and payable for any period prior to the
effective date of termination), nor will any expiration or termination of this Agreement preclude either Party from pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement. In
the event of termination of this Agreement pursuant to Section 8.2(b), 8.2(c) or 8.2(e), in addition to any other rights or remedies [...***...] may have arising under this Agreement or by law, [...***...]. The provisions set forth
in Sections 8.3 and 9 shall remain in full force and effect and survive any termination of this Agreement. 
  

	9	MISCELLANEOUS 

 9.1
Force Majeure. The Parties shall be exempt from liability in respect of any failure to perform their obligations under this Agreement due to circumstances beyond their reasonable control, including but not limited to those arising from:
(i) war, acts of terrorism, fire, epidemic, flood or other acts of God, explosion, civil commotion, strike, lock-out or labor disturbances, acts, regulations or laws of any government, or failure of public utilities or common carriers,
(ii) inability to procure raw materials (other than dextrose) due to shortages of raw materials, or (iii) prevention from or hindrance in 

  

					
		  	7	  	***Confidential Treatment Requested

 
obtaining energy or other utilities. The Party so affected shall give written notice to the other Party of any such force majeure event and shall use its good faith efforts to avoid or remove
such causes of non-performance and to continue performance whenever such causes are removed. Should the event(s) of force majeure suffered by a Party extend beyond a three (3)-month period, the other Party may then terminate this Agreement by
written notice to the non-performing Party, with the consequences of such termination as set forth in Section 8.3. 
 9.2
Notices. Except as expressly set forth to the contrary in this Agreement, all notices, requests, or consents provided for or permitted to be given under this Agreement must be in writing and must be given either by depositing that
writing in the United States mail, addressed to the recipient, postage paid, and registered or certified with return receipt requested or by delivering that writing to the recipient in person, by courier, or by facsimile transmission; and a notice,
request, or consent given under this Agreement is effective on receipt by the person to receive it. All notices, requests, and consents to be sent to a Party must be sent to or made at the following addresses (or such other address as that a Party
may specify by notice to the other Party). 
  

			
	 If to T&L:
	 	 Tate & Lyle Ingredients Americas, Inc.
 2200 East Eldorado Street
 Decatur, IL 62521

Attention: General Counsel
 Facsimile: (217)
421-2935

		
	 with a copy to:
	 	 Tate & Lyle Ingredients Americas, Inc.
 2200 East Eldorado Street
 Decatur, IL 62521

Attention: President
 Facsimile: (217)
421-4765

		
	 If to Genomatica, to:
	 	 Genomatica, Inc.
 10520
Wateridge Circle
 San Diego, CA 92121

Attention: Chief Technology Officer
 Facsimile:
(858) 824-1772

		
	 with a copy to:
	 	 Cooley LLP
 4401 Eastgate
Mall
 San Diego, CA 92121
 Attention:
Kay Chandler
 Facsimile: (858) 550-6420

 Whenever any notice is required to be given by law or this Agreement, a written waiver thereof, signed by the person
entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice. 

  
 8 

 9.3 Entire Agreement; Superseded. This Agreement, together with the Annexes hereto,
and the JDA (and exhibits thereto) constitute the entire agreement of the Parties relating to the subject matter hereof and thereof and supersede all prior contracts or agreements with respect to the development of a process for Bio BDO, whether
oral or written, including the NDA. 
 9.4 Effect of Waiver or Consent. A waiver or consent, express or implied, to or of
any breach or default by any Party in the performance by that Party of its obligations is not a consent or waiver to or of any other breach or default in the performance by that Party of the same or any other obligations of that Party. Failure on
the part of a Party to complain of any act of any Party or to declare the other Party in default, irrespective of how long that failure continues, does not constitute a waiver by that Party of its rights with respect to that default until the
applicable statute-of-limitations period has run. 
 9.5 Amendment or Modification. This Agreement may be amended,
modified, or supplemented only by a written instrument duly executed by each of the Parties to, which instrument shall specifically indicate that it is the desire of the Parties to amend, modify or supplement this Agreement, and similarly may be
waived only by a written instrument duly executed by the waiving Party. 
 9.6 Amendment or Modification. This Agreement
may be amended, modified, or supplemented only by a written instrument duly executed by each of the Parties to this Agreement, which instrument shall specifically indicate that it is the desire of the Parties to amend, modify or supplement this
Agreement, and similarly may be waived only by a written instrument duly executed by the waiving Party. 
 9.7 Binding
Act. This Agreement is binding on and inures to the benefit of the Parties and their respective heirs, legal representatives, successors, and assigns. 
 9.8 Governing Law. THIS AGREEMENT IS GOVERNED BY AND SHALL BE CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, EXCLUDING ANY CONFLICT-OF-LAWS RULE OR PRINCIPLE THAT MIGHT REFER THE
GOVERNANCE OR THE CONSTRUCTION OF THIS AGREEMENT TO THE LAW OF ANOTHER JURISDICTION. 
 9.9 Severability. If any
provision of this Agreement or the application thereof to any Person or circumstance is held invalid or unenforceable to any extent, the remainder of this Agreement and the application of that provision to other Persons or circumstances is not
affected thereby and that provision shall be enforced to the greatest extent permitted by Law. 
 9.10 Further
Assurances. In connection with this Agreement and the transactions contemplated hereby, each Party shall execute and deliver any additional documents and instruments and perform any additional acts that may be necessary or appropriate to
effectuate and perform the provisions of this Agreement and those transactions. 

  
 9. 

 9.11 No Third Party Beneficiaries. The provisions hereof are solely for the benefit
of the Parties and are not intended to, and shall not be construed to, confer a right or benefit on any other Person. 
 9.12
Counterparts. This Agreement may be executed in any number of counterparts with the same effect as if all signing Parties had signed the same document. All counterparts shall be construed together and constitute the same instrument.

 9.13 Assignability. Unless expressly provided otherwise in this Agreement, no Party shall have the right to assign or
otherwise transfer its rights or obligations under this Agreement, except with the written consent of the other Party, not to be unreasonably withheld or delayed; provided, however, that a Party may, without the other Party’s consent, assign or
otherwise transfer its rights or obligations under this Agreement to (a) a successor in interest to all or substantially all of the business of such Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or
otherwise, or (ii) any Affiliate. In the event of any assignment of this Agreement by a Party to an Affiliate pursuant to this Section 9.13, the assigning Party shall remain liable and responsible to the non assigning Party hereto for the
performance and observance of all such rights and obligations by such Affiliate. Any assignment of this Agreement in contravention of this Section 9.13 shall be null and void. 

9.14 Resolutions of Disputes. 
  

	 	(a)	The Parties will use commercially reasonable efforts to resolve any dispute through good faith negotiations. If within [...***...] of any dispute being notified
to the other Party the dispute has not been satisfactorily concluded, then unless otherwise agreed, the Parties shall refer the dispute to the President of T&L and the Chief Executive Officer of Genomatica. If within [...***...] of the
dispute being referred to the individuals referenced in the prior sentence the dispute has not been satisfactorily concluded, then either Party may (but is not required to) refer the dispute for resolution pursuant to Section 9.14(b).

  

	 	(b)	Following negotiations pursuant to Section 9.14(a), any remaining dispute, controversy, or claim arising under, out of or relating to this Agreement (and
subsequent amendments thereof), its validity, binding effect, interpretation, performance, breach or termination, including tort claims, shall be finally determined by arbitration administered by the American Arbitration Association under its
Commercial Arbitration Rules, as in force at the time when the arbitration is initiated. The arbitral tribunal shall consist of three (3) mutually acceptable arbitrators. The place of arbitration shall be [...***...]. Judgment on the
award rendered by the arbitrators may be entered in any court having jurisdiction thereof. 

  

					
		  	10	  	***Confidential Treatment Requested

 9.15 Headings and Recitals. The headings and recitals used herein are for ease of
reference and information and do not affect the interpretation of the Article to which they relate or the interpretation of this Agreement in any other respect. 
 9.16 Confidential Information. All Confidential Information of a Party disclosed or made available pursuant to this Agreement shall be treated as Confidential Information under the JDA. 

[signature page follows] 

  
 11 

 IN WITNESS hereof, the Parties have caused this Agreement to
be executed as of the Signature Date. 
  

	
	TATE & LYLE INGREDIENTS AMERICAS, INC.
	
	By: /s/ Matt Wineinger
	
	Title: President
	
	Date: 3/7/11
	
	GENOMATICA, INC.
	
	By: /s/ William Baum
	
	Title: Executive Chairman
	
	Date: 3/12/11

 SIGNATURE PAGE TO SERVICES
AGREEMENT (DP) 

 Annex A 
 Products 
 Polymer-grade Bio-BDO produced in the manner described in the JDA 

 Annex B 
 Insurance for the Lab Facility, the Pilot Plant and the Equipment 

 [...***...] 

  

					
		  		  	***Confidential Treatment Requested

 [...***...] 

  

					
		  		  	***Confidential Treatment Requested

 Annex C 
 Raw Materials 
 [...***...] 

  

					
		  		  	***Confidential Treatment Requested

 Annex D 
 Specifications for Dextrose 

 

 
 Specification Sheet 

 
 [...***...] 

(Product Specifications) 
  

[...***...] 
 FDA Status:

 [...***...] 

Recommended Storage Conditions: 

[...***...] 
 Shelf Life:

 [...***...] 
 Revised
[...***...] 
  
  

											
	Tate & Lyle	  	2200 E. Eldorado Street	  	Decatur, IL 62525	  	Phone: 217/423-4411	  	Fax: 217/421-2216	  	www.tateandlyle.com 

  

The information contained in this bulletin should not be construed as recommending the use of our product
in violation of any patent, or as warranties (expressed or implied) of non infringement or its fitness for any particular purpose. Prospective purchasers are invited to conduct their own tests, studies and regulatory review to determine the fitness
of Tate & Lyle products for their particular purposes product claims or specific applications. 

  

					
		  	1	  	***Confidential Treatment Requested

 

 
 [...***...] 
 MATERIAL SAFETY DATA SHEET 
  

	
	  
 SECTION 1                CHEMICAL PRODUCTS & COMPANY IDENTIFICATION

Tate &
Lyle                                         
                               [...***...] 

2200 E. Eldorado
Street                                        
             [...***...] 
 Decatur, IL
62521                                        
                      [...***...] 
 TRADE NAME: [...***...] 
 SYNONYMS: [...***...] 

SUBSTANCE: [...***...] 
 CAS NUMBER:
[...***...] 
 CREATED BY: [...***...] 
 CREATION DATE: [...***...] 

	
	  
 SECTION 2                COMPOSITION/INFORMATION ON INGREDIENTS

[...***...] 
  

					
	COMPONENT	  	CASRN	  	EXPOSURE LIMITS
	[...***...]	  		  	[...***...]

	
	  
 SECTION 3                HAZARDS IDENTIFICATION

POTENTIAL ACUTE HEALTH EFFECTS FROM: [...***...] 
 INHALATION: [...***...] 
 SKIN CONTACT: [...***...] 

EYE CONTACT: [...***...] 
 INGESTION:
[...***...] 
 CARCINOGEN STATUS: 

OSHA: [...***...] 
 NTP: [...***...]

 IARC: [...***...] 

	
	  
 SECTION 4                FIRST AID MEASURES

INHALATION: [...***...] 
 SKIN CONTACT:
[...***...] 

  

					
		  	2	  	***Confidential Treatment Requested

 

 
 [...***...] 
 EYE CONTACT: [...***...] 
 INGESTION: [...***...] 

 
  

	
	 SECTION
5                    FIREFIGHTING MEASURES

 FIRE AND EXPLOSION HAZARD: [...***...] 
 EXTINGUISHING MEDIA: [...***...] 

FIREFIGHTING: [...***...] 
 FLAMMABLE
LIMITS: [...***...] 
 FLAMMABILITY CLASS (OSHA): [...***...] 
 HAZARDOUS COMBUSTION PRODUCTS: [...***...] 
  

	
	  
 SECTION 6                    ACCIDENTAL RELEASE MEASURES

OCCUPATIONAL SPILL: [...***...] 
  

	
	  
 SECTION 7                    HANDLING AND STORAGE

STORAGE: [...***...] 
 HANDLING:
[...***...] 
 PACKAGING MATERIALS: [...***...] 
  

	
	  
 SECTION 8                    EXPOSURE CONTROLS/PERSONAL PROTECTION

EXPOSURE LIMITS: [...***...] 

VENTILATION: [...***...] 
 EYE PROTECTION:
[...***...] 
 EMERGENCY WASH FACILITIES: [...***...] 
 SPECIAL, PROTECTIVE CLOTHING: [...***...] 
 GLOVES: [...***...] 

RESPIRATOR: [...***...] 
 FOR FIREFIGHTING
AND OTHER IMMEDIATELY DANGEROUS TO LIFE OR HEALTH CONDITIONS: [...***...] 
  

	
	  
 SECTION 9                    PHYSICAL AND CHEMICAL PROPERTIES

DESCRIPTION: [...***...] 

  

					
		  	3	  	***Confidential Treatment Requested

 

 
 [...***...] 
 ODOR: [...***...] 
 MOLECULAR WEIGHT: [...***...] 

MOLECULAR FORMULA: [...***...] 
 BOILING
POINT: [...***...] 
 MELTING POINT: [...***...] 
 VAPOR PRESSURE: [...***...] 
 VAPOR DENSITY: [...***...] 

SPECIFIC GRAVITY: [...***...] 
 WATER
SOLUBILITY: [...***...] 
 BAUME at 100°F: [...***...] 
 TOTAL SOLIDS: [...***...] 
 MOISTURE: [...***...] 

pH: [...***...] 
 VISCOSITY at 135°F:
[...***...] 
 WEIGHT lbs./gal at 135°F: [...***...] 

 
  

	
	SECTION 10                    STABILITY AND REACTIVITY

  
 REACTIVITY:
[...***...] 
 CONDITIONS TO AVOID: [...***...] 
 INCOMPATIBILITIES: [...***...] 
 HAZARDOUS DECOMPOSITION: [...***...] 

POLYMERIZATION: [Will not occur.] 
  

 

	
	SECTION 11                    TOXICOLOGY INFORMATION

  
 ACUTE HEALTH
EFFECTS: 
 INHALATION: [...***...] 
 SKIN CONTACT: [...***...] 
 EYE CONTACT: [...***...] 

INGESTION: [...***...] 
 CHRONIC HEALTH
EFFECTS: [...***...] 
  
  

	
	SECTION 12                    ECOLOGICAL INFORMATION

  
 ACUTE AQUATIC
TOXICITY: [...***...] 
 DEGRADABILITY: [...***...] 
 BIOCONCENTRATION FACTOR (BCF): [...***...] 
 OCTANOL/WATER PARTITION COEFFICIENT:
[...***...] 
  
  

	
	SECTION 13                    DISPOSAL INFORMATION

  
 Follow local,
state and federal regulations for product disposal. Not a hazardous waste unless contaminated with hazardous products. 

  

					
		  	4	  	***Confidential Treatment Requested

 

 
 [...***...] 
  

	
	  
 SECTION 14                TRANSPORTATION INFORMATION

D.O.T. CLASSIFICATION: [...***...]. 
 UN
NUMBER: [...***...] 
  

	
	  
 SECTION 15                REGULATORY INFORMATION

US FEDERAL REGULATIONS: 
 Clean Air Act: ODS:
[...***...] 
 TSCA STATUS: [...***...] 
 SARA (EPCRA) SECTION 313 (40 C.F.R. § 372.65): [...***...] 
 STATE REPORTING
REQUIREMENTS: 
 California Proposition 65: [...***...] 
  

	
	  
 SECTION 16                OTHER

 Copyright 2007, 2008 Tate & Lyle. All rights reserved. 
  

 

  

					
		  	5	  	***Confidential Treatment RequestedJoint Development Agreement

 Exhibit 10.22 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

JOINT DEVELOPMENT AGREEMENT 
 This Joint Development Agreement (this “JDA”), is dated as of this 15th day of April, 2011 (“Effective Date”), by and between Genomatica, Inc., a Delaware corporation with
principal offices located at 10520 Wateridge Circle, San Diego, California 92121 (hereinafter referred to as “Genomatica”), and Chemtex Italia S.r.l., an Italian corporation with principal offices located at Strada Ribrocca n. 11,
15057 Tortona (AL), Italy (hereinafter referred to as “Chemtex”). 
 RECITALS: 

WHEREAS, Genomatica has invented and developed proprietary technology and recombinant microorganisms to produce 1,4-butanediol
(“Bio-BDO”); 
 WHEREAS, Chemtex has invented and developed the proprietary PROESATM process, which
converts Biomass to cellulosic sugars; 
 WHEREAS, Genomatica and Chemtex have evaluated the economic feasibility of a
biological route for the manufacture of Bio-BDO using Biomass cellulosic sugars; 
 WHEREAS, Genomatica and Chemtex mutually
desire to join their respective strengths in a relationship for the joint development of a process combining their respective processes for producing renewable Bio-BDO from Biomass feedstocks; and 

WHEREAS, each Party recognizes it may be necessary or desirable to grant to the other Party access to certain intellectual property in
order to carry out the objectives of this JDA. 
 NOW THEREFORE, Genomatica and Chemtex agree to the following terms and
conditions: 
 ARTICLE I 
 DEFINITIONS 
 1.1. Previously Defined Terms. Each term defined in
the preamble and the Recitals to this JDA shall have the meaning set forth above whenever used herein. 
 1.2.
Definitions. In addition to the terms defined in the preamble and the Recitals of this JDA, the following terms, whenever used herein, shall have the meanings set forth below: 

1.2.1 “Affiliate” shall mean, with respect to any specified Person, any other Person that directly, or indirectly
through one or more intermediaries, controls, is controlled by, or is under common control with, such specified Person, and for this 

  
 1 

 
purpose, “control,” “controlled by” and “common control” shall mean the ownership and voting control of more than 50% of the outstanding voting securities or
interest in capital or profits of such specified Person, or the right to direct or control the management or affairs of such specified Person by contract or similar arrangement. Should a Person divest an Affiliate or should an Affiliate cease to
satisfy this definition, such Affiliate’s rights and obligations under this JDA shall be terminated. 
 1.2.2
“Background Intellectual Property” shall mean all Intellectual Property first conceived, reduced to practice and/or otherwise acquired or obtained by a Party prior to the Effective Date of this JDA or outside of the course of the
Joint Development Program and during the term of this JDA, including rights arising in the course of prosecution and maintenance of such Intellectual Property, which such Party discloses or otherwise provides to the other Party for use in the Joint
Development Program. 
 1.2.3 “Bio-BDO Field” shall mean the biological manufacture of Bio-BDO from sugars
produced from Biomass and the marketing and the sale of Bio-BDO manufactured from sugars produced from Biomass, and includes research and development related to the foregoing. 
 1.2.4 “Biomass” shall mean any non-food agriculture plant (such as but not limited to poplar, eucalyptus and energy crops) and agricultural waste (such as but not limited to straw, corn
stover and sugar cane bagasse) that can be used as a renewable non-food feedstock for the production of sugars (which non-food feedstock excludes, without limitation, first generation food feedstocks of corn, wheat, sugar beets and sugar cane).

 1.2.5 “Bioprocess” shall mean a fermentation process using microorganisms for the production of Bio-BDO, and
including the downstream Bio-BDO purification steps. 
 1.2.6 “Chemtex Confidential Information” shall mean any
Confidential Information of Chemtex. 
 1.2.7 “Chemtex Intellectual Property” shall mean (a) all
Background Intellectual Property owned or licensed (with the right to grant licenses or sublicenses) by Chemtex which claims or covers all or part of the PROESATM Process Technology, and (b) all JDA Intellectual Property owned by Chemtex.

 1.2.8 “Commercialization KPIs” shall have the meaning set forth in Section 3.1(b). 

1.2.9 “Commercial Process” shall have the meaning set forth in Section 2.1. 

1.2.10 “Confidential Information” shall mean any and all proprietary information and materials, in any form (written,
oral, photographic, electronic, magnetic, or otherwise), including without limitation, information related to technical, business, and 

  
 2 

 
intellectual property matters, intellectual property including know-how, data, trade secrets, and all documents and other physical materials relating to prototypes, materials, compositions,
devices, methods, or procedures related to the research and development, manufacture, use or sale of Bio-BDO. Confidential Information of a Party disclosed pursuant to the NDA shall be treated as Confidential Information under this JDA. The Chemtex
Intellectual Property shall be Confidential Information of Chemtex, and the Genomatica Intellectual Property shall be Confidential Information of Genomatica. 
 1.2.11 “Damages” shall have the meaning set forth in Section 13.1. 
 1.2.12 “Development Plan” shall mean the plan for activities to be conducted under the Joint Development Program which is set forth in Schedule 1.2.12, including deliverables, estimated
timelines and budget, which may be amended by the JDC pursuant to Section 5.2. 
 1.2.13 “Facilities”
shall mean the Chemtex facilities located in Rivalta Scrivia (AL) – Italy. 
 1.2.14 “Genomatica Confidential
Information” shall mean any Confidential Information of Genomatica. 
 1.2.15 “Genomatica Intellectual
Property” shall mean (a) all Background Intellectual Property owned or licensed (with the right to grant licenses or sublicenses) by Genomatica, which claims or covers all or part of a Bioprocess, including the components (including
Genomatica Microorganisms) used in a Bioprocess, (b) all Process Intellectual Property, and (c) all JDA Intellectual Property owned by Genomatica. 
 1.2.16 “Genomatica Microorganism(s)” shall mean microorganisms designated by Genomatica and identified in Schedule 1.2.16 and which may be supplied by Genomatica during the term of the
Joint Development Program. 
 1.2.17 “Intellectual Property” shall mean all (a) Patent Rights,
(b) trademarks, service marks, domain names, trade dress, logos, trade names, and corporate names and registrations and applications for registration thereof, (c) copyrights and registrations and applications for registration thereof,
(d) computer software, data, and documentation, (e) trade secrets and confidential business information, whether patentable or unpatentable and whether or not reduced to practice, know-how, manufacturing and production processes and
techniques, research and development information, copyrightable works, financial, marketing and business data, pricing and cost information, business and marketing plans and customer and supplier lists and information, (f) other proprietary
rights relating to any of the foregoing, and (g) copies and tangible embodiments thereof. 
 1.2.18 “JDA
Intellectual Property” shall mean all Intellectual Property first conceived, reduced to practice and/or otherwise acquired or obtained solely by a Party or jointly by the Parties in the course of and during the term of the Joint Development
Program, including rights arising in the course of prosecution and 

  
 3 

 
maintenance of such Intellectual Property, but excluding all Process Intellectual Property. 
 1.2.19 “Joint Development Committee” or “JDC” shall mean the joint committee established pursuant to Article V. 

1.2.20 “Joint Development Program” shall mean the joint program undertaken by the Parties under this JDA as described in
Articles II and III. 
 1.2.21 “Law” shall mean any federal, state, regional, local, or foreign law,
constitution, rule, statute, ordinance, regulation, order, code, judgment, charge, writ, injunction, or decree. 
 1.2.22
“MOU” shall have the meaning set forth in Section 1.2.32. 
 1.2.23 “NDA” shall mean the
nondisclosure agreement between the Parties dated 19 March 2010 between M&G Finanziaria S.r.l. and Genomatica and covering also M&G Finanziaria Affiliates, which includes Chemtex. 

1.2.24 “Party” shall mean Genomatica or Chemtex, as the case may be, and “Parties” shall mean
Genomatica and Chemtex. 
 1.2.25 “Patent Rights” shall mean any patent application, certificate of invention,
application for certificate of invention, priority patent filing or patent (foreign or domestic), including any and all divisionals, continuation (in whole or in part), request for continued examination, reissues, reexaminations, additions,
substitution cases, confirmations, registrations, revalidations, revisions, renewals and extensions thereof. 
 1.2.26
“Person” shall mean an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint venture, joint stock company, government (or an agency or political subdivision
thereof) or other entity of any kind. 
 1.2.27 “Pilot Phase” shall have the meaning set forth in
Section 2.2. 
 1.2.28 “Pilot Plant Facility” shall have the meaning set forth in Section 2.1.

 1.2.29 “Process Intellectual Property” shall mean all Intellectual Property relating to all or
part of a Bioprocess, including any components (including microorganisms) used in a Bioprocess, and/or the basic engineering package that uses or incorporates the Bioprocess, which Intellectual Property is first conceived, reduced to practice and/or
otherwise acquired or obtained solely by a Party or jointly by the Parties in the course of and during the term of the Joint Development Program, including rights arising in the course of prosecution and maintenance of such Intellectual Property.
For clarification, Process Intellectual Property excludes all Background Intellectual Property. 

  
 4 

 1.2.30 “PROESATM Intellectual Property” shall mean all Intellectual
Property relating to all or part of PROESATM Process Technology, including any components used in PROESATM Process Technology, and/or the basic engineering package that uses or incorporates the PROESATM Process Technology, which
Intellectual Property is first conceived, reduced to practice and/or otherwise acquired or obtained solely by a Party or jointly by the Parties in the course of and during the term of the Joint Development Program, including rights arising in the
course of prosecution and maintenance of such Intellectual Property. For clarification, PROESATM Intellectual Property excludes all Background Intellectual Property. 
 1.2.31 “PROESATM License” shall have the meaning set forth in Section 3.3. 
 1.2.32 “PROESATM License Agreement” shall mean the license in the Bio-BDO Field granted by Chemtex to Genomatica for the use of the PROESATM Technology, PROESATM Intellectual
Property and Chemtex Intellectual Property in the Commercial Process where the scope of the license and the applicable conditions are as set out in the “Biomass to Chemicals Partnership Memorandum of Understanding (MOU)” between Genomatica
and Gruppo M&G dated February 14, 2011 (hereinafter referred to as the “MOU”). The MOU is attached hereto as Schedule 1.2.36. 
 1.2.33 “PROESATM Process Technology” shall mean the process configuration, operating parameters and conditions, the equipment set up and/or the equipment design to produce fermentable
sugar or precursor of fermentable sugar from Biomass [...***...]. For clarification, PROESATM Process Technology does not include any technology (including, but not limited to, process configuration, operating parameters and conditions,
equipment set up and/or equipment design) with respect to any portion of a process using fermentable sugar, including, without limitation, any process for fermentation of fermentable sugars. 

1.2.34 “Representatives” shall mean, with respect to any Person, the directors, officers, employees, agents, Affiliates,
or other representatives of such specified Person, including, without limitation, financial advisors, consultants, and counsel. 

1.2.35 “Territory” shall mean the world. 
 1.2.36 “Third Party(ies)” shall mean any Person other than Genomatica and its Affiliates or Chemtex and its Affiliates. 

1.2.37 “Third Party Agreement” shall have the meaning set forth in Section 3.3. 

  

					
		  	5	  	***Confidential Treatment Requested

 ARTICLE II 
 JOINT DEVELOPMENT PROGRAM OBJECTIVES 
 2.1. Objectives. The purpose
of the Parties’ relationship under this JDA is to further develop Genomatica’s current Bioprocess at the Chemtex’s PROESATM pilot plant located at the Facilities (the “Pilot Plant Facility”) to produce Bio-BDO
from cellulosic sugars produced from Biomass feedstocks by modifying the Pilot Plant Facility to develop Genomatica’s current Bioprocess into a continuous or semi-continuous commercially viable Bioprocess for producing Bio-BDO from cellulosic
sugars generated using Biomass feedstocks via PROESATM Process Technology (collectively, the “Commercial Process”) at a competitive cash cost relative to petroleum-based BDO. The Parties also desire to discuss options to work
together to commercialize in the Territory, Bio-BDO produced using the Commercial Process and Biomass feedstocks at a commercial manufacturing facility co-located with a Third Party. 

2.2. Pilot Phase. During the period of performance of the Joint Development Program (the “Pilot Phase”), the
objective is to demonstrate the ability to manufacture Bio-BDO via the Bioprocess using cellulosic sugars generated from Biomass feedstocks via the PROESATM Process Technology in the Pilot Plant Facility. The principal tasks in the Pilot Phase
shall consist of those matters set forth in the Development Plan. 
 ARTICLE III 

PILOT PHASE 
 3.1. Pilot Phase. 
 (a) During the Pilot Phase, the
responsibility of the Parties for costs and expenses will be as set forth in Schedule 3.1(a). Without the approval of the JDC, neither Party will incur any capital expenditures in the performance of the Pilot Phase except as expressly set forth in
the Development Plan. 
 (b) [...***...]. The JDC will determine whether the technical and commercial key
performance indexes (KPIs) for the Pilot Phase, as set forth in the Development Plan (the “Commercialization KPIs”) have been satisfied. The Pilot Phase will continue until the date that the principal tasks in the Development Plan
(and any other tasks reasonably determined by Genomatica) have been completed, whether or not the Commercialization KPIs have been satisfied. 
 3.2. Deliverables. 
 1. Genomatica Deliverables. 

(a) During the Pilot Phase, Genomatica will be responsible for (i) transferring to the Pilot Plant Facility
[...***...] which will be subject to review by Chemtex, with the [...***...] approved by the JDC and will comply with safety and environmental standards 

  

					
		  	6	  	***Confidential Treatment Requested

 
required for activities conducted at the Pilot Plant Facility, and (ii) completing the [...***...], in each case subject to having sufficient data regarding the Pilot Plant Facility to
enable such activities. 
 (b) During the Pilot Phase, Genomatica will be responsible for providing information
regarding Genomatica’s actual Bioprocess costs for use in jointly developed cost models,which are currently cost advantaged relative to petroleum-based BDO plant costs, using dextrose. These costs will be subject to review by Chemtex, through
the JDC. 
 2. Chemtex Deliverables. 

(a) During the Pilot Phase, Chemtex will be responsible [...***...]. 

(b) During the Pilot Phase, Chemtex will be responsible for the following: 

(i) providing Biomass feedstock to produce cellulosic sugars; 

(ii) providing engineering and manufacturing expertise and experience to [...***...]; and 

(iii) providing Bio-BDO product support services, including [...***...]. 

(c) During the Pilot Phase, Chemtex will be responsible for providing information regarding Chemtex’s actual cost for
PROESATM Process Technology based upon a Biomass standard cost of [...***...] $/t d.m. for use in jointly developed cost models. These costs will be subject to review by Genomatica, through the JDC. 

3. Joint Deliverables. The Parties will be jointly responsible for the following deliverables under the Development Plan:

 (a) jointly developing the overall process cost model, including the PROESATM cellulosic sugar cost model
and the Bio-BDO cost model, that is required to manufacture competitive Bio-BDO; and 
 (b) preparing the PDP for
the overall process on the basis of the result of the Pilot Phase, and 
 (c) coordinating any external
communications regarding the Development Plan. 

  

					
		  	7	  	***Confidential Treatment Requested

 3.3. Commercialization Structure. During the Pilot Phase, the Parties will discuss
how to work together to commercialize Bio-BDO in the Territory using the Commercial Process. [...***...]. 
 ARTICLE IV

 COMMERCIALIZATION 
 4.1. Commercialization Process License. Upon completion of the Pilot Phase, provided that the Bio-BDO produced in the Pilot Phase meets minimum standards of quality and costs, applicable to
petroleum-based BDO, which specifications are described on Schedule 4.1, Genomatica will enter into Third Party Agreement discussions and provide written notice to Chemtex identifying the potential Third Party licensee. Genomatica will bear
all expenses it incurs in executing Third Party Agreements. 
 4.2. Negotiation of PROESATM License Agreement. The
Parties will negotiate in good faith the definitive agreements for the PROESATM License Agreement for the commercialization of Bio-BDO produced using the Commercial Process, including the PROESATM Process Technology, in the Territory.

 4.3. Supply of Biomass Feedstock. [...***...]. 

ARTICLE V 

GOVERNANCE OF THE JOINT DEVELOPMENT PROGRAM 
 5.1. Formation of Joint Development Committee (JDC). Promptly following the Effective Date, the Parties shall form the JDC, and each Party will appoint two of its employees to serve on the JDC. The
purpose of the JDC is to oversee, guide, and monitor the conduct of the Joint Development Program under the terms of this JDA. To ensure the success of the Joint Development Program, the JDC will meet regularly and at least quarterly to review the
progress towards the objectives of the Joint Development Program. Such meetings may be held in person, or by any means of telecommunications 

  

					
		  	8	  	***Confidential Treatment Requested

 
or video conference, as the JDC members deem necessary or appropriate. The JDC will keep minutes of its meetings, including at a minimum who is in attendance, the subject matter discussed or
considered, and any action taken. Decisions of the JDC will be made by unanimous approval, with the representatives of Genomatica collectively having one vote and the representatives of Chemtex collectively having one vote. If the JDC is unable to
reach agreement on any matter properly before it, then either Party may, by written notice to the other Party, have such matter referred for resolution pursuant to Section 14.14. 

5.2. Responsibilities of JDC. The JDC shall have the following responsibilities and authority: 

 

	 	(a)	to provide a means of communication between the Parties regarding the Joint Development Program; 

 

	 	(b)	subject to and within the parameters of the Development Plan, to monitor and oversee the implementation of the Development Plan; 

 

	 	(c)	to review and approve any amendments or modifications to the Development Plan; and 

 

	 	(d)	such other responsibilities as expressly assigned to the JDC under this JDA or by written agreement of the Parties. 

5.3. Reservation of Rights. Matters outside the scope of the Joint Development Program and internal to each Party are not under
the purview of the JDC. Such matters include but are not limited to internal personnel policies and programs, budgeting, finance, commercial and marketing strategies, and business decisions. However, the Parties agree to communicate with each other
promptly on those matters which, while outside the scope of the Joint Development Program, nevertheless may reasonably be expected to affect the Joint Development Program. 
 5.4. Independent Contractors. Each party is an independent contractor and shall retain complete control and responsibility for its own operations and employees. Nothing in this JDA shall be
construed to constitute either Party as a partner, agent or representative of the other Party. Neither Party shall have the right or authority to assume or create any obligation on behalf of or in the name of the other, or to bind the other in any
manner whatsoever. 
 ARTICLE VI 
 ADDITIONAL OBLIGATIONS OF CHEMTEX 
 6.1. Supply of Storage Equipment and
Instrumentation. Chemtex shall supply [...***...]. 

  

					
		  	9	  	***Confidential Treatment Requested

 6.2. Installation of Equipment and Instrumentation. Chemtex shall coordinate the
installation of all equipment and instrumentation (including any Genomatica-supplied equipment or instrumentation) at the Facilities. The equipment and instrumentation, together with the Facilities, shall be accessible, upon reasonable prior notice,
to Genomatica employees assigned to support the Joint Development Program. 
 6.3. Services. Chemtex shall supply
(i) technical and engineering services for the Facilities and (ii) employees to operate the Facilities. 
 6.4.
Access to Information and Data. Chemtex shall provide Genomatica reasonable access to all Confidential Information, technical information, and data used during and data generated from the startup and operation of the Facilities. 

ARTICLE VII 

ADDITIONAL OBLIGATIONS OF GENOMATICA 
 7.1. [...***...]. During the Pilot Phase and in accordance with the Development Plan, Genomatica shall [...***...] pursuant to this JDA. 

7.2. [...***...] [....***...] required to be supplied by Genomatica under the Development Plan as well as [...***...]
defined in detail in the Development Plan. 
 7.3. Availability of Technical Employees. Genomatica shall make available
such technical employees at the Facilities reasonably required by Chemtex to assist in the development of the Bioprocess as provided in the Development Plan. Genomatica shall cause its employees to comply with Chemtex’s safety, health, and
environmental policies and procedures. 
 ARTICLE VIII 

INTELLECTUAL PROPERTY 
 8.1. Background Intellectual Property. Each Party acknowledges and agrees that, as between the Parties, each Party is and shall remain the sole and exclusive owner of all right, title, and interest
in and to its Background Intellectual Property, and that this JDA does not affect such ownership. Each Party acknowledges that it acquires no rights under this JDA to the other Party’s Background Intellectual Property other than the limited
rights specifically granted in this JDA. 
 8.2. Process Intellectual Property. All Process Intellectual Property, other
than the PROESATM Intellectual Property, will be owned by Genomatica. Chemtex hereby irrevocably transfers, conveys and assigns to Genomatica all of its right, title, and interest in the Process Intellectual Property, other than the PROESATM
Intellectual Property, and agrees to execute such documents, render such assistance, and take such other action as Genomatica may reasonably request, at Genomatica’s expense, to apply for, register, perfect, confirm, and protect
Genomatica’s ownership rights in such Process Intellectual 

  

					
		  	10	  	***Confidential Treatment Requested

 
Property. The Parties shall use commercially reasonable efforts to promptly disclose and jointly identify all Process Intellectual Property during the term this JDA. Under the PROESATM
License Agreement, Chemtex will grant to Genomatica the exclusive right under the Chemtex Intellectual Property and PROESATM Intellectual Property to use the PROESATM Process Technology with and as part of the Commercial Process. Chemtex
shall render such assistance, and take such other action as Genomatica may reasonably request, to protect Genomatica’s license rights in the Chemtex Intellectual Property and PROESATM Intellectual Property. 

8.3. JDA Intellectual Property. JDA Intellectual Property first conceived or reduced to practice solely by employees and/ or
consultants of a Party shall be owned solely by such Party, and JDA Intellectual Property first conceived or reduced to practice jointly by employees and/or consultants of both Parties shall be owned [...***...]. A Party shall have the
exclusive right to apply for or register any patents and other proprietary protections with respect to the JDA Intellectual Property solely owned by such Party, including, for example, improvements, modifications, or uses of existing technology in
different areas. The Parties through the JDC shall agree which Party shall apply for and register any patents and other proprietary protections with respect to the [...***...], and shall cooperate in such activities, including sharing copies
of filings with adequate time for review and comment by the other Party, and assembling inventorship information and data for filing such patent applications. Each Party shall have the right to use and practice, and grant licenses to use and
practice, all [...***...], without the consent of or any duty of accounting to the other Party; provided that Chemtex shall not have the right to use and practice, or grant licenses to use and practice, [...***...] for the development,
production, sale and distribution of BDO; and provided that Genomatica shall not have the right to use and practice, or grant licenses to use and practice, [...***...]. 
 8.4. No Implied Licenses. No license or right is granted by implication or otherwise with respect to any patent application or patent except as may be specifically set forth in this JDA. Chemtex
and Genomatica will promptly notify the other in writing if such Party (a) becomes aware of any Intellectual Property of a Third Party that would be infringed by the activities under the Joint Development Program, (b) receives a written
claim or notice of infringement of any Intellectual Property of a Third Party related to the activities under the Joint Development Program or (c) is sued for infringement of any Intellectual Property of a Third Party as a result of the
activities under the Joint Development Program. 
 ARTICLE IX 

GRANT OF RIGHTS 
 9.1. Limited License for Joint Development Program. Subject to the terms and conditions of this JDA, Genomatica hereby grants to Chemtex a non-exclusive, non-sublicensable (except to Chemtex’s
Affiliates), royalty-free license to use Genomatica Intellectual Property directly relevant to the Joint Development Program within the Pilot 

  

					
		  	11	  	***Confidential Treatment Requested

 
Plant Facility, solely for purposes of performing Chemtex’s obligations under the Joint Development Program during the term of this JDA. Subject to the terms and conditions of this JDA,
Chemtex hereby grants to Genomatica a non-exclusive, non-sublicensable (except to Genomatica’s Affiliates), royalty-free license to use Chemtex Intellectual Property and PROESATM Intellectual Property directly relevant to the Joint
Development Program within the Territory solely for purposes of performing Genomatica’s obligations under the Joint Development Program during the term of this JDA. If a Party grants a sublicense of the license under this Section 9.1 to
any of its Affiliates, such Party shall cause its Affiliates to comply with all obligations of such Party hereunder, including, without limitation, Articles VIII and X; provided that such Party shall at all times be fully responsible for the
performance of such Affiliate. 
 9.2. Reservation of Rights to Intellectual Property. Chemtex reserves all rights under
the Chemtex Intellectual Property and PROESATM Intellectual Property, subject only to the license granted to Genomatica in Section 9.1, and Genomatica reserves all rights under the Genomatica Intellectual Property, subject only to the
licenses granted to Chemtex in Section 9.1. Notwithstanding anything to the contrary in this JDA, the Parties acknowledge and agree that general knowledge about operation of the Facilities learned or observed in the course of the Joint
Development Agreement may be used by either Party. 
 9.3. Mutual Agreements. Chemtex agrees not to practice the
Genomatica Intellectual Property and the JDA Intellectual Property developed jointly by the Parties, and Genomatica agrees not to practice the Chemtex Intellectual Property, PROESATM Intellectual Property and the JDA Intellectual Property
developed jointly by the Parties, in each case except as expressly permitted in this JDA or other written agreement between the Parties. 
 9.4. No Use of Names. Except as otherwise provided herein, no right, express or implied, is granted by this JDA to use in any manner the name “Chemtex” or “Genomatica” or any
other trademark, service mark, or trade name of the other Party in connection with the performance of this JDA. 
 ARTICLE X

 CONFIDENTIAL INFORMATION 
 10.1. Confidentiality. Each Party (in such capacity, the “receiving Party”) agrees to maintain the confidentiality of, and not disclose to any other Person, all Confidential Information
of the other Party (in such capacity, the “disclosing Party”) and not to use the Confidential Information of the other Party except for the purposes of this JDA or pursuant to the terms of a Commercialization Agreement, in each case for
[...***...] from the Effective Date of this JDA. The obligation of confidentiality, nondisclosure and nonuse shall not apply to Confidential Information which: 
  

	 	(a)	is or becomes public through no fault of the receiving Party; 

  

					
		  	12	  	***Confidential Treatment Requested

	 	(b)	is known by the receiving Party at the time of disclosure as shown by prior written records; 

 

	 	(c)	is disclosed to the receiving Party by a Third Party entitled to disclose it without obligation of confidentiality, [...***...]

 

	 	(d)	[...***...]. 

 10.2.
Permitted Disclosures. Each Party may disclose Confidential Information belonging to the other Party: 

(a) to its own employees or consultants who are subject to binding obligations concerning confidential information and
inventions, to the extent such disclosure is reasonably necessary in connection with the activities contemplated by this JDA, provided that the disclosing Party shall be responsible for any breach thereof by its own employees or consultants;

 (b) to the extent such disclosure is reasonably necessary for filing or prosecuting patents as expressly
permitted by Article VIII; or 
 (c) to the extent such disclosure is reasonably necessary for prosecuting or
defending litigation or complying with applicable laws, rules or governmental regulations, providing that in the event a Party is required to make a disclosure of the other Party’s Confidential Information pursuant to this clause (c), it shall,
except where impracticable or not permitted by Law, give reasonable advance notice to the other Party of such disclosure and use commercially reasonable efforts, at the cost of the other Party, to secure confidential treatment of such information.

 10.3. Permitted Disclosure of Material Terms of this JDA. A Party shall have the right to disclose the material terms
of this JDA (a) to any Person retained by such Party to perform legal, accounting, engineering or similar services and who have a need to know such terms in order to provide such services and (b) to Third Parties in connection with due
diligence or similar investigations by such Third Parties, provided that any such Person or Third Party is bound to confidentiality obligations consistent in all material respects with the terms of this Article X. 

10.4. Publicity. In any event, each Party agrees to take all reasonable action to avoid disclosure of the other Party’s
Confidential Information hereunder. Promptly following the Effective Date, the Parties will coordinate issuing a press release concerning this JDA (which may be a joint press release or separate press releases by each Party), subject to mutual
agreement of the Parties on the content of such press release. If either Party desires to, or is required by Law or stock exchange requirements to, make a public announcement concerning this JDA or the subject matter hereof after such initial press
release, such Party shall give reasonable prior advance notice of the proposed text of such announcement to the other Party for its prior review and comment. 

  

					
		  	13	  	***Confidential Treatment Requested

 10.5. JDA Terms Are Confidential Information of Both Parties. Except for public
statements agreed to by the Parties or for disclosures that are in the reasonable judgment of a Party required by Law or stock exchange listing requirements, the Parties agree that the existence, material terms, and the subject matter of this JDA
shall be considered Confidential Information of both Parties. 
 10.6. Equitable Remedies. Each Party acknowledges and
agrees that the other Party’s remedies at law for breach or threatened breach of any of the provisions of this Article 10 would be inadequate and, in recognition of that fact, in the event of any such breach or threatened breach, it is agreed
that, in addition to other remedies to which it may be entitled, the other Party will be entitled to equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction without the necessity of
posting bond, or any other equitable remedy which may then be available; provided, that nothing herein contained will be construed as prohibiting the non-breaching Party from pursuing any other remedies available to it for such breach or threatened
breach, including recovery of damages from such breaching Party. 
 ARTICLE XI 

REPRESENTATIONS AND WARRANTIES 
 11.1. Representations and Warranties of Genomatica. Genomatica represents and warrants to Chemtex as of the Effective Date that: 

(a) Genomatica is a corporation, duly incorporated, validly existing and in good standing under the laws of the State of
Delaware. Genomatica has all requisite power and authority to carry on its business and to own and use the assets and properties owned and used by it. 
 (b) Genomatica has all requisite power and authority to execute and deliver this JDA and to perform its obligations hereunder. The execution and delivery of this JDA by Genomatica and the performance by
Genomatica of its obligations hereunder have been duly and validly authorized by all necessary action on the part of Genomatica. This JDA has been duly and validly executed and delivered by Genomatica and, assuming the due authorization, execution
and delivery by Chemtex, constitutes a valid and binding obligation of Genomatica enforceable against Genomatica in accordance with its terms. 
 (c) The execution and delivery of this JDA by Genomatica and the performance by Genomatica of its obligations hereunder, does not and will not, as the case may be, (i) conflict with or violate any
provision of the Certificate of Incorporation or the Bylaws of Genomatica, (ii) conflict with, result in a breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of, create in any
party the right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver under, any contract, agreement or arrangement (written or oral), franchise or permit to which Genomatica is a party or by which Genomatica is bound,
(iii) result in the 

  
 14 

 
imposition of any lien, claim, charge or encumbrance upon any Genomatica Intellectual Property, or (iv) violate any Law applicable to Genomatica. 

(d) There is no action, suit, proceeding, claim, or investigation pending or threatened against Genomatica, in any court
or by or before any governmental authority, or before any arbitrator of any kind, which, if adversely determined, would restrict the ability of Genomatica to perform its obligations hereunder. Genomatica knows of no basis for any such action, suit,
claim, investigation, or proceeding. 
 (e) Genomatica is the exclusive owner of the Background Intellectual
Property included in the Genomatica Intellectual Property, and it has the right to grant Chemtex the limited license under Section 9.1 without conflict with the rights of any Third Party, or has secured all necessary and appropriate consents to
license the same. 
 (f) The Background Intellectual Property included in the Genomatica Intellectual Property is
not subject to any claims, encumbrances, liens, licenses, judgments and/or security interests that could reasonably be expected to have an adverse effect on the right to practice such Background Intellectual Property in the Bio-BDO Field, and none
of the Background Intellectual Property included in the Genomatica Intellectual Property is the current subject of any litigation, interference or opposition proceeding. 

(g) Genomatica is unaware of any publications or activities (including, without limitation, patents, articles, and public
uses or sales) by it or others, which could reasonably be expected to invalidate any claim(s) of any patent or patent application within the Background Intellectual Property included in the Genomatica Intellectual Property. 

(h) Genomatica is not aware of any valid Third Party Intellectual Property that could reasonably be expected to be
infringed or asserted to be infringed by practice of the Background Intellectual Property included in the Genomatica Intellectual Property in the performance of the Joint Development Program pursuant to this JDA. 

(i) Genomatica has and will continue to have the legal power to extend the rights granted to Chemtex in this JDA with
respect to Process Intellectual Property and JDA Intellectual Property owned by Genomatica, and it has not made and will not make any commitments to others inconsistent with or in derogation of such rights. 

(j) Genomatica has, and will through the term of this JDA, cause its employees who work on the Joint Development Program
to disclose to it inventions within the scope of JDA Intellectual Property or Process Intellectual Property and to assign to it rights in such inventions, it being understood that if 

  
 15 

 
due care and diligence are used, any inadvertent failure to comply with this Section 11.1(j) will not constitute a breach of this JDA. 

11.2. Representations and Warranties of Chemtex. Chemtex represents and warrants to Genomatica as of the Effective Date that:

 (a) Chemtex is a corporation validly existing and in good standing under the laws of the country of Italy.
Chemtex has all requisite power and authority to carry on its business and to own and use the assets and properties owned and used by it. 
 (b) Chemtex has all requisite power and authority to execute and deliver this JDA and to perform its obligations hereunder. The execution and delivery of this JDA by Chemtex and the performance by Chemtex
of its obligations hereunder have been duly and validly authorized by all necessary action on the part of Chemtex. This JDA has been duly and validly executed and delivered by Chemtex and, assuming the due authorization, execution and delivery by
Genomatica, constitutes a valid and binding obligation of Chemtex enforceable against Chemtex in accordance with its terms. 
 (c) The execution and delivery of this JDA by Chemtex and the performance by Chemtex of its obligations hereunder, does not and will not, as the case may be, (i) conflict with or violate any
provision of the Certificate of Incorporation or By-Laws of Chemtex, (ii) conflict with, result in a breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of, create in any party
the right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver under, any contract, agreement or arrangement (written or oral), franchise or permit to which Chemtex is a party or by which Chemtex is bound,
(iii) result in the imposition of any lien, claim, charge or encumbrance upon any Chemtex Intellectual Property, or (iv) violate any Law applicable to Chemtex. 

(d) There is no action, suit, proceeding, or material claim or investigation pending or threatened against Chemtex, in any
court or by or before any governmental authority, or before any arbitrator of any kind, which, if adversely determined, would restrict Chemtex’s ability to perform its obligations hereunder. Chemtex knows of no basis for any such action, suit,
claim, investigation, or proceeding. 
 (e) Chemtex is the exclusive owner of the Background Intellectual
Property included in the Chemtex Intellectual Property, and it has the right to grant Genomatica the limited license under Section 9.1 without conflict with the rights of any Third Party, or has secured all necessary and appropriate consents to
license the same. 
 (f) The Background Intellectual Property included in the Chemtex Intellectual Property is
not subject to any claims, encumbrances, liens, licenses, 

  
 16 

 
judgments and/or security interests that could reasonably be expected to have an adverse effect on the right to practice such Background Intellectual Property in the Bio-BDO Field, and none of
the Background Intellectual Property included in the Chemtex Intellectual Property is the current subject of any litigation, interference or opposition proceeding. 

(g) Chemtex is unaware of any publications or activities (including, without limitation, patents, articles, and public
uses or sales) by it or others, which could reasonably be expected to invalidate any claim(s) of any patent or patent application within the Background Intellectual Property included in the Chemtex Intellectual Property. 

(h) Chemtex is not aware of any Third Party Intellectual Property that could reasonably be expected to be infringed or
asserted to be infringed by practice of the Background Intellectual Property included in the Chemtex Intellectual Property in the performance of the Joint Development Program pursuant to this JDA. 

(i) Chemtex has and will continue to have the legal power to extend the rights granted to Genomatica in this JDA with
respect to Chemtex Intellectual Property, PROESATM Intellectual Property and JDA Intellectual Property owned by Chemtex, and it has not made and will not make any commitments to others inconsistent with or in derogation of such rights.

 (j) Chemtex has, and will through the term of this JDA, cause its employees who work on the Joint Development
Program to disclose to it inventions within the scope of JDA Intellectual Property, PROESATM Intellectual Property or Process Intellectual Property and to assign to it rights in such inventions, it being understood that if due care and diligence
are used, any inadvertent failure to comply with this Section 11.2(j) will not constitute a breach of this JDA. 
 11.3.
Notice of Developments. The Parties will give prompt written notice to each other of (a) any event or development causing a breach of any of their respective representations and warranties contained in this JDA, (b) any failure to
comply with or satisfy any covenant or agreement to be complied with by such Party hereunder and (c) any event or development that, individually or in the aggregate, could reasonably be expected to result in a breach of any of their respective
representations and warranties contained in this JDA or the failure to comply with or satisfy any covenant or agreement to be complied with by such Party hereunder. No disclosure by any Party pursuant to this Section 11.3, however, shall be
deemed to prevent or cure any misrepresentation, breach of warranty or breach of covenant. During the term of this JDA, no Party shall take any action or agree to take any action, either orally or in writing, that could reasonably be expected to
result in a breach of any of their respective representations and warranties contained in this JDA or any failure to comply with or satisfy any covenant or agreement to be complied with by such Party hereunder. 

  
 17 

 11.4 DISCLAIMER OF WARRANTIES. Except as specifically provided in this Article XI,
each Party disclaims all warranties of any kind, express or implied, to the fullest extent permitted by Law, including but not limited to the implied warranties of merchantability, fitness for particular purpose and noninfringement. NEITHER PARTY
MAKES ANY REPRESENTATION OR WARRANTY WITH REGARD TO THE SUCCESS OF THE JOINT DEVELOPMENT PROGRAM OR THE USEFULNESS OF ANY BACKGROUND INTELLECTUAL PROPERTY, PROCESS INTELLECTUAL PROPERTY OR JDA INTELLECTUAL PROPERTY. 

ARTICLE XII 

INDEMNIFICATION 
 12.1. Indemnification by Genomatica. Genomatica shall indemnify, defend, and hold harmless Chemtex and its Representatives from and against any and all damages, losses, liabilities, judgments,
awards, costs, and expenses of any nature whatsoever, including reasonable attorneys’ fees and court costs (collectively, “Damages”), incurred by any of them as a result of (a) any Third Party claims, actions, suits or
proceedings arising from any breach of any representation, warranty, covenant or agreement of Genomatica herein or (b) any Third Party claims that the practice of the Background Intellectual Property included in the Genomatica Intellectual
Property in the performance of the Joint Development Program pursuant to this JDA infringes Intellectual Property of such Third Party. 
 12.2. Indemnification by Chemtex. Chemtex shall indemnify, defend, and hold harmless Genomatica and its Representatives from and against any and all Damages incurred by any of them as a result of
(a) any Third Party claims, actions, suits or proceedings arising from any breach of any representation, warranty, covenant or agreement of Chemtex herein or (b) any Third Party claims that the practice of the Background Intellectual
Property included in the Chemtex Intellectual Property in the performance of the Joint Development Program pursuant to this JDA infringes Intellectual Property of such Third Party. 

12.3. Control of Defense. Except as specifically provided in this section, any Person entitled to indemnification under this
Article XII shall give written notice to the indemnifying Party of any claims that may be subject to indemnification, promptly after learning of such claim, and the indemnifying Party shall assume the defense of such claims with counsel reasonably
satisfactory to the indemnified party. If such defense is assumed by the indemnifying Party with counsel so selected, the indemnifying Party will not be subject to any liability for any settlement of such claims made by the indemnified party without
its consent (but such consent will not be unreasonably withheld or delayed), and will not be obligated to pay the fees and expenses of any separate counsel retained by the indemnified party with respect to such claims. 

12.4. Remedies. No remedy set forth in this JDA is intended to be exclusive of any other remedy. Each remedy shall be in addition
to every other remedy provided hereunder, or now or hereafter existing at law, in equity, by statute, or otherwise. 

  
 18 

 ARTICLE XIII 
 TERM AND TERMINATION 
 13.1. Termination by the Parties. This JDA
may be terminated: 
 (a) by mutual written consent of Chemtex and Genomatica; 

(b) by Genomatica in the event Chemtex has breached in any material respect any representation, warranty, covenant or
agreement of Chemtex contained in this JDA, Genomatica has notified Chemtex of the breach, and the breach has continued without cure for a period of thirty (30) days after the notice of breach; 

(c) by Chemtex in the event Genomatica has breached in any material respect any representation, warranty, covenant or
agreement of Genomatica contained in this JDA, Chemtex has notified Genomatica of the breach, and the breach has continued without cure for a period of thirty (30) days after the notice of breach; 

Any termination of this JDA pursuant to Section 13.1 shall be effective upon the delivery of written notice of the terminating Party to the other
Party. 
 13.2. Automatic Termination. This JDA shall automatically terminate, unless the Parties agree otherwise, upon:

 (a) the mutual decision by the Parties to discontinue the Joint Development Program; 

(b) the expiration of five years from the Effective Date; or 

(c) the date on which Genomatica enters into a Third Party Agreement. 

13.3. Effect of Termination. Upon termination of this JDA pursuant to this Article XIII all rights and obligations of the Parties
under this JDA shall terminate, except as provided in this Section 13.3. Upon termination of this JDA, Genomatica shall have the right to remove at its cost any equipment or materials that it has supplied or paid for pursuant to
Section 7.2 hereof, provided that it elects to exercise that right within 60 days after the date of termination. Termination of this JDA shall not relieve or release either Party of any right or obligation which, at the time of such
termination, has already accrued to such Party or which is attributable to a period prior to such termination, nor will any expiration or termination of this JDA preclude either Party from pursuing all rights and remedies it may have under this JDA,
at law or in equity, with respect to breach of this JDA. The provisions set forth in Sections 9.2, 9.3, 9.4, 11.4 and 13.3 and Articles I, VIII, X, XII and XIV shall remain in full force and effect and survive any termination of this JDA. The
expiration or termination of this JDA shall not affect any PROESATM License Agreement entered into prior to such expiration or termination, which shall remain in effect in accordance with its terms. 

  
 19 

 ARTICLE XIV 
 GENERAL TERMS 
 14.1. Non-Solicitation. During the term of this JDA
and for a period of [...***...] after the termination of this JDA, unless otherwise agreed to by the Parties, each Party agrees that it will not and will not permit its Affiliates to directly or indirectly solicit for employment or consulting
any employee of the other Party or its Affiliates; provided that in no event will listing or advertising any employee or consultant position in any publicly available source or hiring or engaging any person who contacts a Party or its Affiliate
based upon such listing or advertisement be a breach of this Section 14.1. 
 14.2. Force Majeure. The Parties shall
be exempt from liability in respect of any failure to perform their obligations under this JDA due to circumstances beyond their reasonable control, including but not limited to those arising from: (i) war, acts of terrorism, fire, epidemic,
flood or other acts of God, explosion, civil commotion, strike, lock-out or labor disturbances, acts, regulations or laws of any government, or failure of public utilities or common carriers, (ii) inability to procure raw materials due to
shortages of raw materials, or (iii) prevention from or hindrance in obtaining energy or other utilities. The Party so affected shall give written notice to the other Party of any such force majeure event and shall use its good faith efforts to
avoid or remove such causes of non-performance and to continue performance whenever such causes are removed. Should the event(s) of force majeure suffered by a Party extend beyond a three (3)-month period, the other Party may then terminate this JDA
by written notice to the non-performing Party, with the consequences of such termination as set forth in Section 13.3. 

14.3. Notices. Except as expressly set forth to the contrary in this JDA, all notices, requests, or consents provided for
or permitted to be given under this JDA must be in writing and must be given either by depositing that writing in the United States mail, addressed to the recipient, postage paid, and registered or certified with return receipt requested or by
delivering that writing to the recipient in person, by courier, or by facsimile transmission; and a notice, request, or consent given under this JDA is effective on receipt by the person to receive it. All notices, requests, and consents to be sent
to a Party must be sent to or made at the following addresses (or such other address as that a Party may specify by notice to the other Party). 
  

			
	 If to Chemtex:
	  	Chemtex Italia S.r.l.
		  	Strada Ribrocca n. 11
		  	15057 Tortona (AL) Italy
		  	Attention: Corporate R&D Director
		  	Facsimile: (39) 0131-81-1759

  

					
		  	20	  	***Confidential Treatment Requested

			
	 with a copy to:
	  	Chemtex International Inc.
		  	1979 Eastwood Road
		  	Wilmington, NC 28403
		  	Attention: General Counsel
		  	Facsimile: (910) 509-4567
		
	 If to Genomatica, to:
	  	Genomatica, Inc.
		  	10520 Wateridge Circle
		  	San Diego, CA 92121
		  	Attention:    Chief Technology Officer
		  	Facsimile:    (858) 824-1772
		
	 with a copy to:
	  	Cooley LLP
		  	4401 Eastgate Mall
		  	San Diego, CA 92121
		  	Attention: Kay Chandler
		  	Facsimile: (858) 550-6420

 Whenever any notice is required to be given by law or this JDA, a written waiver thereof, signed by the person entitled
to notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice. 
 14.4.
Entire Agreement; Superseded. This JDA, together with the Exhibits hereto and the MOU and, as applicable, the PROESATM License Agreement, constitutes the entire agreement of the Parties relating to the subject matter hereof and thereof
and supersedes all prior contracts or agreements with respect to the development of a process for Bio-BDO, whether oral or written, including the NDA. 
 14.5. Effect of Waiver or Consent. A waiver or consent, express or implied, to or of any breach or default by any Party in the performance by that Party of its obligations is not a consent or
waiver to or of any other breach or default in the performance by that Party of the same or any other obligations of that Party. Failure on the part of a Party to complain of any act of any Party or to declare the other Party in default,
irrespective of how long that failure continues, does not constitute a waiver by that Party of its rights with respect to that default until the applicable statute-of-limitations period has run. 

14.6. Amendment or Modification. This JDA may be amended, modified, or supplemented only by a written instrument duly executed by
each of the Parties to, which instrument shall specifically indicate that it is the desire of the Parties to amend, modify or supplement this JDA, and similarly may be waived only by a written instrument duly executed by the waiving Party.

 14.7. Binding Act. This JDA is binding on and inures to the benefit of the Parties and their respective heirs,
legal representatives, successors, and assigns. 

  
 21 

 14.8. Governing Law. THIS JDA IS GOVERNED BY AND SHALL BE CONSTRUED IN ACCORDANCE
WITH THE LAWS OF THE STATE OF DELAWARE, EXCLUDING ANY CONFLICT-OF-LAWS RULE OR PRINCIPLE THAT MIGHT REFER THE GOVERNANCE OR THE CONSTRUCTION OF THIS JDA TO THE LAW OF ANOTHER JURISDICTION. 

14.9. Severability. If any provision of this JDA or the application thereof to any person or circumstance is held invalid or
unenforceable to any extent, the remainder of this JDA and the application of that provision to other persons or circumstances is not affected thereby and that provision shall be enforced to the greatest extent permitted by Law. 

14.10. Further Assurances. In connection with this JDA and the transactions contemplated hereby, each Party shall execute and
deliver any additional documents and instruments and perform any additional acts that may be necessary or appropriate to effectuate and perform the provisions of this JDA and those transactions. 

14.11. No Third Party Beneficiaries. The provisions hereof are solely for the benefit of the Parties and are not intended to, and
shall not be construed to, confer a right or benefit on any other person. 
 14.12. Counterparts. This JDA may be
executed in any number of counterparts with the same effect as if all signing Parties had signed the same document. All counterparts shall be construed together and constitute the same instrument. 

14.13. Assignability. Unless expressly provided otherwise in this JDA, no Party shall have the right to assign or otherwise
transfer its rights or obligations under this JDA, except with the written consent of the other Party, not to be unreasonably withheld or delayed; provided, however, that a Party may, without the other Party’s consent, assign or otherwise
transfer its rights or obligations under this JDA to (a) a successor in interest to all or substantially all of the business of such Party to which this JDA relates, whether by merger, sale of stock, sale of assets or otherwise, or
(ii) any Affiliate. In the event of any assignment of this JDA by a Party to its Affiliate pursuant to this Section 14.13, the assigning Party shall remain liable and responsible to the non-assigning Party hereto for the performance and
observance of all such rights and obligations by such Affiliate. Any assignment of this JDA in contravention of this Section 14.13 shall be null and void. 
 14.14. Resolutions of Disputes. 
 (a) The Parties will use
commercially reasonable efforts to resolve any dispute through good faith negotiations. If within [...***...] of any dispute being notified to the other Party the dispute has not been satisfactorily concluded, then unless otherwise agreed, the
Parties shall refer the dispute to the Chief Executive Officer of Chemtex and the Chief Executive Officer of Genomatica. If within [...***...] of the dispute being referred to the individuals referenced in the prior sentence the dispute has
not been 

  

					
		  	22	  	***Confidential Treatment Requested

 
satisfactorily concluded, then either Party may (but is not required to) refer the dispute for resolution 
pursuant to Section 14.14(b). 
 (b) Following negotiations pursuant to Section 14.14(a), any
remaining dispute, controversy, or claim arising under, out of or relating to this JDA (and subsequent amendments thereof), its validity, binding effect, interpretation, performance, breach or termination, including tort claims, shall be finally
determined by arbitration administered by the American Arbitration Association under its Commercial Arbitration Rules, as in force at the time when the arbitration is initiated. The arbitral tribunal shall consist of three (3) mutually
acceptable arbitrators. The place of arbitration shall be [...***...]. Judgment on the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. 

14.15. Headings and Recitals. The headings and recitals used herein are for ease of reference and information and do not affect
the interpretation of the Article to which they relate or the interpretation of this JDA in any other respect. 
 14.16.
Limitation of Liability. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ITS AFFILIATES FOR ANY SPECIAL OR CONSEQUENTIAL DAMAGES, REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT, IN TORT INCLUDING NEGLIGENCE, BY STATUTE OR
UNDER ANY QUASI-CONTRACTUAL THEORY OF LIABILITY, EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. The foregoing limitations of liability and damages will not apply and nothing in this JDA shall affect either Party’s
liability for breach of any obligation specified in Article X or either Party’s indemnification obligations under Article XII. 
 [signature page follows] 

  

					
		  	23	  	***Confidential Treatment Requested

 IN WITNESS WHEREOF, the Parties caused this Joint Development Agreement to be executed by
their duly authorized and empowered representatives as of the Effective Date. 
  

	
	CHEMTEX ITALIA S.R.L.
	
	 By: /s/ Illegible

	
	 Title: Chief Technology Officer

	
	GENOMATICA, INC.
	
	 By: /s/ William Baum

	
	 Title: Executive Chairman

  

SIGNATURE PAGE TO JOINT DEVELOPMENT AGREEMENT

 SCHEDULE 1.2.12 

DEVELOPMENT PLAN 
  

	 	1.	Definition of the [...***...] 

  

	 	2.	Delivery of [...***...] 

  

	 	3.	Definition of [...***...] 

  

	 	4.	Definition of [...***...] 

  

	 	5.	APPROVAL OF [...***...] 

  

	 	6.	Execution of [...***...] 

  

	 	7.	Start up of the plant 

  

	 	8.	Operation of the pilot plant. 

  

	 	9.	[...***...] 

 During operation the
following aspect will be tested: 
 [...***...] 
 TIMING: 
 [...***...] 
 Commercialization KPIs 
 Overall process that [...***...] 

Quality: [...***...] 

  

					
		  		  	***Confidential Treatment Requested

 Schedule 1.2.16 

GENOMATICA MICROORGANISMS 
 [...***...] 

  
 1 

 SCHEDULE 1.2.32 

MOU 

Biomass to Chemicals Partnership 
 Memorandum of Understanding (MOU) 
 (Non-Binding) 

February 14, 2011 
  

 
  

					
	 

	 		  	

  
  

The purpose of the MOU is to set forth the basis for a series of Agreements establishing a partnership between Gruppo M&G and Genomatica for the
development and commercialization of process technologies to produce major basic and intermediate chemicals from biomass. This MOU is intended by the parties to be non-binding, does not contain all of the terms necessary to effect the transactions
contemplated hereby, and if the parties wish to proceed with the transaction, the terms of any such agreements effecting the transaction shall be embodied in a definitive agreement or agreements. 

  
 1 

 [...***...] 
 Gruppo M&G and Genomatica seek to enter into a partnership that will lead the way for commercial production of major industrial chemicals from biomass, [...***...] Together the companies will
[...***...] enabling the conversion of cellulosic biomass into major industrial chemicals, [...***...] The partnership will begin in Q2’11 with a focus on 1,4-butanediol (BDO) [...***...]. In addition the parties may enter
into a third aspect of the partnership to pursue the production of [...***...]. 
  

	 	1.	Gruppo M&G Background 

Gruppo M&G is privately held company in Italy owned by the Ghisolfi family with [...***...] (“PROESATM technology”). Chemtex is currently building a 45KT cellulosic
ethanol facility in Crescentino, Italy [...***...]. 
  

	 	2.	Genomatica Background 

 Genomatica is a
privately-held venture capital backed company in the US. Genomatica aims to become the leading sustainable chemicals company in the world in terms of both the production of sustainable chemicals as well as the development of innovative process

  

					
		  	2	  	***Confidential Treatment Requested

 
technologies to convert renewable feedstocks into chemicals. Genomatica has developed a novel bioprocess that offers the first low-cost direct route for the production of renewable BDO. This
process will deliver a cost-advantage versus the current production of BDO from hydrocarbon feedstocks. Genomatica is currently driving initial commercial production of Bio-BDO from dextrose in the US to demonstrate the process at commercial scale
targeting initial production from an integrated facility by the end of 2013, with possible toll manufacturing of the first Bio-BDO in 2012. In addition Genomatica has established intellectual property that forms the basis of other bioprocesses
targeting 20+ basic and intermediate chemicals, and seeks to develop processes for many of these chemicals including [...***...]. 
  

	 	3.	Scope 

 [...***...]: 

 

	 	1.	 Development and Commercialization of Biomass to BDO – In the coming months Genomatica and Chemtex will aim to establish a joint development
agreement to develop the complete biomanufacturing process for making BDO from cellulosic biomass (2G-BDO,
2nd generation BDO process), and drive a path for the
initial commercialization in [...***...]. 

 [...***...]. 

  

					
		  	3	  	***Confidential Treatment Requested

 [...***...] 

 

	 	4.	Development and Commercialization of Biomass to BDO 

 [...***...] 
 It is the desire of M&G/Chemtex and Genomatica to coordinate on impactful
public announcements around the partnership for biomass to chemicals. 
 [...***...] 

  

					
		  	4	  	***Confidential Treatment Requested

 Chemtex-Genomatica Exclusive Joint Development Agreement for Biomass to BDO 

Genomatica and Chemtex will form an exclusive partnership to develop and license a commercial process for biomass to BDO integrating
PROESATM technology with Genomatica BDO fermentation
technology and relevant needed separation technology. (2G-BDO) 
 [...***...] 

Genomatica’s current BDO process will [...***...] use biomass feedstock derived from the Chemtex PROESA technology. The combined process will
then be demonstrated at approximately a 1 ton/day of biomass scale in an integrated demonstration plant that will be operational in H1’12 that will be similar to the existing pilot plant in Rivalta that has been the basis for generating the
basic engineering package for the current commercial cellulosic ethanol facility being constructed in Crescentino. 

[...***...] 
  

  

					
		  	5	  	***Confidential Treatment Requested

 [...***...] 
  

  

					
		  	6	  	***Confidential Treatment Requested

 M&G-Chemtex-Genomatica Commercial Agreement for Biomass to BDO 

Genomatica and M&G will agree to engage in exploring the first commercial plant for producing BDO from biomass. Genomatica will drive the
commercialization as part of its BDO business, and M&G (directly or through a nominated third party) will at a minimum provide guaranteed off-take of a certain quantity of BDO for [...***...]. Initial commercialization will target
[...***...]. Initial estimated capacity is 20-45KT. 
 [...***...] 

 

  

					
		  	7	  	***Confidential Treatment Requested

 [...***...] 
 As part of this partnership, Genomatica and M&G will enter into a Sponsored Research Agreement that will begin in [...***...]. 

[...***...] 
  

  

					
		  	8	  	***Confidential Treatment Requested

 [...***...] 

 

			
	GRUPPO M&G	  	GENOMATICA, INC.
		
	 Signature:
                                        
            
	  	Signature:                           
                                 
		
	 Name:
                                        
                  
	  	Name:                            
                                      
		
	 Title:
                                        
                    
	  	Title:                            
                                        

		
	 Date:
                                        
                    
	  	Date:                            
                                        

  

					
		  	9	  	***Confidential Treatment Requested

 SCHEDULE 3.1(a) 

RESPONSIBILITY OF PARTIES FOR EXPENSES 
  

			
	 ITEM
	  	 Responsibility

	 Genomatica Personnel cost and travelling expenses both in Genomatica lab and in Chemtex Lab
	  	[...***...]
	 Chemtex Personnel cost and travelling expenses both in Genomatica lab and in Chemtex Lab
	  	[...***...]
	 Cost of biomass feedstock for testing and running pilot plant
	  	[...***...]
	 Equipment, instrumentation and installation cost needed to modify the pilot line in order to produce 2G-BDO
	  	[...***...]
	 Cost of BDO disposal if not used for testing
	  	[...***...]
	 Cost of preparation of PDP
	  	[...***...]
	 All activities for product storage, testing
	  	[...***...]
	 Sample delivery
	  	[...***...]

  

					
		  	1	  	***Confidential Treatment Requested

 Schedule 4.1 
 BDO Specification 
 [...***...] 

 

  

					
		  	1	  	***Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]